Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

June 6th 2023

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

HER3-DXd Elicits Responses and Safety in Heavily Pretreated ER+ Breast Cancer and TNBC

June 5th 2023

Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.

Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

June 5th 2023

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

June 5th 2023

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

June 5th 2023

The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.

Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer

June 4th 2023

Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

June 3rd 2023

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Dr Champ on the Consideration of Using Radiation Therapy in Breast Cancer

June 2nd 2023

Colin E. Champ, MD, discusses the importance of considering the use of radiation therapy for patients with breast cancer and details ongoing research into this arena.

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

June 2nd 2023

Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.

Dr Yuan on the Importance of Clinical Trial Enrollment in Breast Cancer

June 1st 2023

Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.

HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast Cancer

June 1st 2023

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

May 31st 2023

Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.

Dr Hilton on the Potential Impact of the CompassHER2-pCR Trial in HER2+ Breast Cancer

May 30th 2023

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Improvements in Personalized Medicine Allow for Greater Exploration of Treatment De-escalation in Breast Cancer

May 30th 2023

Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.

HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

May 29th 2023

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

May 28th 2023

Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.

Dr Champ on Boost Radiotherapy in Breast Cancer

May 26th 2023

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

May 25th 2023

A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes.